Novartis Venture Fund is among the participants in a series A round disclosed by the exosite drug developer at its public launch.

The WuXi AppTec-backed cancer drug developer has now raised $70m in total as it prepares to bring its lead candidate into the clinic.

Tufts Health Plan, DaVita Venture Group, Wanxiang America and Salesforce Ventures helped the multicultural patient engagement platform reach $24m in overall funding.

Fudan University’s Furong Investment has co-led a round for Singlera Genomics, which will use the cash to advance its pipeline of cancer screening products.

CR Pharma was among the investors in a $45.8m round that pushed the gene therapy developer's funding to about $170m in the past 14 months.

Eli Lilly and Jointown-backed Singlera Genomics will put the series B financing into advancing its pipeline of cancer screening products.

UCB Ventures and GV returned for the neurodegenerative, neuromuscular and retinal disease drug developer's series B round.

Drug release technology developer Rani has now raised $211m in all, from investors including GV, Novartis, Ping An Ventures, KPC, AstraZeneca and Stevanato.

Kissei Pharmaceutical has become the cancer immunotherapy developer's first corporate investor, in a series D round bringing its overall funding to $93.5m.

Jafco has led a round of undisclosed size for the All About, Nippon Life, KLab and Credit Saison-backed teleconsultation technology developer, taking its total funding to nearly $20m.